1. Home
  2. DVAX vs ECVT Comparison

DVAX vs ECVT Comparison

Compare DVAX & ECVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • ECVT
  • Stock Information
  • Founded
  • DVAX 1996
  • ECVT 1935
  • Country
  • DVAX United States
  • ECVT United States
  • Employees
  • DVAX N/A
  • ECVT N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • ECVT Major Chemicals
  • Sector
  • DVAX Health Care
  • ECVT Industrials
  • Exchange
  • DVAX Nasdaq
  • ECVT Nasdaq
  • Market Cap
  • DVAX 1.3B
  • ECVT 1.0B
  • IPO Year
  • DVAX 2004
  • ECVT 2017
  • Fundamental
  • Price
  • DVAX $9.70
  • ECVT $9.01
  • Analyst Decision
  • DVAX Buy
  • ECVT Buy
  • Analyst Count
  • DVAX 4
  • ECVT 3
  • Target Price
  • DVAX $26.50
  • ECVT $12.17
  • AVG Volume (30 Days)
  • DVAX 1.9M
  • ECVT 1.5M
  • Earning Date
  • DVAX 11-06-2025
  • ECVT 10-30-2025
  • Dividend Yield
  • DVAX N/A
  • ECVT N/A
  • EPS Growth
  • DVAX N/A
  • ECVT N/A
  • EPS
  • DVAX N/A
  • ECVT N/A
  • Revenue
  • DVAX $316,268,000.00
  • ECVT $723,462,000.00
  • Revenue This Year
  • DVAX $23.23
  • ECVT $14.65
  • Revenue Next Year
  • DVAX $16.57
  • ECVT $2.85
  • P/E Ratio
  • DVAX N/A
  • ECVT N/A
  • Revenue Growth
  • DVAX 26.66
  • ECVT 4.93
  • 52 Week Low
  • DVAX $9.20
  • ECVT $5.24
  • 52 Week High
  • DVAX $14.63
  • ECVT $9.69
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 41.54
  • ECVT 50.75
  • Support Level
  • DVAX $9.20
  • ECVT $9.04
  • Resistance Level
  • DVAX $9.94
  • ECVT $9.41
  • Average True Range (ATR)
  • DVAX 0.30
  • ECVT 0.27
  • MACD
  • DVAX -0.05
  • ECVT -0.00
  • Stochastic Oscillator
  • DVAX 40.65
  • ECVT 23.60

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About ECVT Ecovyst Inc.

Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: Ecoservices and Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.

Share on Social Networks: